BIB241220C59000
- 5.50
- 0.000.00%
Ultra Nasdaq Biotechnology Proshares Newsroom
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Amgen Decline on MariTide Data Could Be Due to Lack of More Details
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
4 Stocks to Watch on Tuesday: AMGN, BBY and More
Anavex Gains After Seeking EU Marketing Nod for Alzheimer's Drug
Amgen Shares Are Trading Lower Following the Results of Its Phase 2 Study With MariTide in Obesity.
Amgen Announced Data At 52 Weeks In Phase 2 Study With MariTide (Maridebart Cafraglutide, Formerly AMG 133) Subcutaneously Administered Monthly Or Less Frequently, Showing Up To ~20% Average Weight Loss At Week 52 Without A Weight Loss Plateau
AstraZeneca Reports Positive Phase 3 Results for Truqap in Prostate Cancer
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
Gilead Acquires Investigational HIV Vaccine From Spanish Biotech Aelix
Looking Into Vertex Pharmaceuticals's Recent Short Interest
S&P 500, Dow Hit Records Right After Open | Live Stock
Price Over Earnings Overview: Gilead Sciences
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Weekly Buzz: Nvidia Falls on Near Perfect Report, but Only For a Day
Catalyst Watch: Robotaxi IPO, OPEC+, Holiday Shopping Data, and Movie Blockbusters
Market Climbs, Bitcoin Close to $100k | Live Stock
3 'Buy' Stocks and 2 'Hold' Stocks According to Oppenheimer